Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
9.340
-0.470 (-4.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 24, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals: Q2 Earnings Insights
December 09, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the...
Via
Benzinga
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 10, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
November 08, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
September 21, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Why KalVista Pharmaceuticals' Stock Is Trading Higher Today
September 15, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of...
Via
Benzinga
Exposures
Product Safety
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
September 14, 2021
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of...
Via
Benzinga
Exposures
Product Safety
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
September 14, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
August 23, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 13, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 12, 2021
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...
Via
Benzinga
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 12, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
July 11, 2021
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...
Via
Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...
Via
Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...
Via
Benzinga
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
June 28, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
June 05, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 27, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.